Coronavirus Update
Novel Coronavirus SARS-CoV-2, the agent responsible for coronavirus disease 2019 (COVID-19), is producing a growing public health emergency in China and elsewhere in the world. As the numbers of confirmed cases and deaths continue to rise, clinical details of COVID-19 disease have become available through case reports and public health partners. However, the complete clinical spectrum is not yet fully understood, and health care providers may not be familiar with the most recent information related to the clinical course, diagnostic tests, and state of treatment strategies for this infection. There is also a need to educate health care providers on the key measures that hospitals and clinics can utilize to prepare for handling Persons Under Investigation (PUI) and reduce exposure of healthcare personnel as well as others. This activity aims to update health care providers regarding the state of the epidemiology, diagnosis, clinical course, and state of treatment strategies for COVID-19 disease caused by the SARS-CoV-2 virus. The activity also aims to provide health care providers with guidance on handling PUI to reduce the risk of transmission.
Target Audience
This CME/CE activity is designed to meet the educational needs of Physicians, Advanced Practice Professionals, Fellows, Residents, Nurses, and Other Health Professionals
Learning Objectives
At the conclusion of the session, the participants should be able to:
- Identify patients who should be evaluated as patients under investigation for SARS-CoV-2 infection
- Incorporate the appropriate procedures for patient isolation, handling and diagnostic testing for patients with suspected COVID-19 disease caused by SARS-CoV-2 infection in their clinics
- Describe the state of the recommended treatment and supportive care strategies for patients with confirmed COVID-19 disease
- Discuss drugs and vaccines in development against the SARS-Cov-2 virus
Mayar Al Mohajer, M.D.
Associate Professor
Department of Medicine, Infectious Disease
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose
Robert Legare Atmar, M.D., Peer Reviewer
Professor
Department of Medicine, Infectious Disease
Baylor College of Medicine
Houston, Texas
Disclosure: Takeda Vaccines, Inc – Research support
Seres Therapeutics, Inc – Data Monitoring Committee
Maria Elena Bottazzi, Ph.D.
Associate Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Baylor College of Medicine
Disclosure: Nothing to Disclose
Peter Hotez, M.D., Ph.D.
Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine
Health Policy Scholar
Baylor College of Medicine
Disclosure: Nothing to Disclose
David McCormick, M.D.
Resident
Department of Medicine, Infectious Disease
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to Disclose
Amy Spallone, M.D.
Fellow
Department of Medicine, Infectious Disease
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to Disclose
Laila Eugenia Woc-Colburn, M.D., Program Director
Associate Professor
Department of Medicine, Infectious Disease
Director of Medical Education
National School of Tropical Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: McGraw Hill, Elsevier – Intellectual property
ASTMH, ISDA – Honorarium recipient
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance